{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:09:53Z","timestamp":1790359793389,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.atherosclerosis.2017.03.039","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T16:47:18Z","timestamp":1490892438000},"page":"116-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction"],"prefix":"10.1016","volume":"260","author":[{"given":"Daisuke","family":"Sueta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Suyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Sueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-2894","authenticated-orcid":false,"given":"Mai","family":"Tomiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsuko","family":"Yamamoto-Ibusuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hokimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2014.20","article-title":"The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014)","volume":"37","author":"Shimamoto","year":"2014","journal-title":"Hypertens. Res."},{"issue":"36","key":"10.1016\/j.atherosclerosis.2017.03.039_bib2","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A\u00a0randomized trial of bevacizumab, an anti\u2013vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2040-7378-5-7","article-title":"Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients\u2013an observational study","volume":"5","author":"Reimann","year":"2013","journal-title":"Exp. Transl. stroke Med."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib5","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/HYPERTENSIONAHA.109.132274","article-title":"Vascular endothelial growth factor inhibitors and hypertension a central role for the kidney and endothelial factors?","volume":"54","author":"Granger","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2017.03.039_bib8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib9","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib12","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/cas.12826","article-title":"Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Kiyota","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib14","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.111.00841","article-title":"Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans","volume":"61","author":"Thijs","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1440-1681.2012.05699.x","article-title":"Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib","volume":"39","author":"Nagasawa","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib17","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.jacc.2004.08.062","article-title":"Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia","volume":"44","author":"Bonetti","year":"2004","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.jacc.2009.10.073","article-title":"Digital assessment of endothelial function and ischemic heart disease in women","volume":"55","author":"Matsuzawa","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1152\/japplphysiol.01285.2005","article-title":"Role of nitric oxide in the regulation of digital pulse volume amplitude in humans","volume":"101","author":"Nohria","year":"2006","journal-title":"J.\u00a0Appl. Physiology"},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib20","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0735-1097(03)00329-2","article-title":"Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease","volume":"41","author":"Bonetti","year":"2003","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib21","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-15-1354","article-title":"Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"22","author":"Ikeda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib24","doi-asserted-by":"crossref","first-page":"H1054","DOI":"10.1152\/ajpheart.1998.274.3.H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am. J. Physiology-Heart Circulatory Physiology"},{"key":"10.1016\/j.atherosclerosis.2017.03.039_bib25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1291\/hypres.28.147","article-title":"Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor\/fetal liver kinase-1\/NO pathway","volume":"28","author":"Miura","year":"2005","journal-title":"Hypertens. Res."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017301429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017301429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T07:40:07Z","timestamp":1568965207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017301429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":25,"alternative-id":["S0021915017301429"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.039","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}